The effect of risedronate on the risk of hip fracture in elderly women.

By R. Goodman. New England Journal of Medicine, 2001

723 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/71f972eaf56a6670d4203aa18b89854538f49791

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Kanis
2. O. Johnell
3. H. Johansson
4. Eugene V. McCloskey
5. J. Reginster
6. A. Odén
7. Chris Cooper
8. F. Borgström

In Orthopedics and Sports Medicine

1. J. Kanis
2. Chris Cooper
3. J. Reginster
4. Eugene V. McCloskey
5. H. Johansson
6. R. Rizzoli
7. on behalf of the International Osteoporosis Foundation
8. A. Odén

In Surgery

1. J. Kanis
2. Chris Cooper
3. Eugene V. McCloskey
4. J. Reginster
5. H. Johansson
6. R. Rizzoli
7. O. Johnell
8. A. Odén

Citations in the corpus

• Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK (2008, background): “For example, patients selected on the basis of risk factors for falling may respond less completely to agents that preserve bone mass than patients selected on the basis of low BMD [53].”
• FRAX™ and the assessment of fracture probability in men and women from the UK (2008, background): “example, patients selected on the basis of risk factors for falling may respond less completely to agents that preserve bone mass than patients selected on the basis of low BMD [89].”
• Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. (2003, result): “The lack of observed benefit on fractures in HERS was interpreted as being consistent with the lack of benefit observed with other agents in women without osteoporosis.(19,20) It is not apparent why the WHI and HERS findings differ because both trials enrolled women without osteoporosis.”
• Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “In addition, a trial evaluating the efficacy of risedronate on the hip was conducted [102].”
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “by 30%, an effect that was greater in osteoporotic women age 70–79 years (− 40%), and not significant in women over the age of 80 years without evidence of osteoporosis [71].”